OpenDNA
Using Precision Genomic AI to Predict and Prevent Heart Disease
Company Overview
Snapshot
Founded in September 2018 by Eran Feldhay and Erez Ornan, OpenDNA operates with 1–10 employees. The company has raised a total of $6.02 million across six funding rounds. In December 2024, OpenDNA secured equity crowdfunding from PipelBiz.
Business overview
OpenDNA is a Health Tech & Life Sciences company specializing in Digital Healthcare and Medical Decision Support. The company develops an AI platform that integrates clinical and genomic data analysis to address polygenic diseases. Its core technology leverages artificial intelligence and machine learning, particularly focusing on genes, to create prediction models that identify high-risk patients and inform targeted prevention strategies. Initially applied to cardiometabolic syndrome, OpenDNA plans to expand its technology to other complex polygenic diseases such as cancer, chronic kidney failure, and autoimmune conditions, serving healthcare providers and insurance companies in markets including the United States and Europe.
Strategic signal
In November 2023, OpenDNA partnered with PartnerMD to offer AI-based genetic risk testing for cardiometabolic diseases to patients. This collaboration signals a strategic move to expand market reach and validate the clinical utility of OpenDNA's genomic AI platform, demonstrating its potential for broader adoption in personalized medicine and preventative healthcare.
Log in to access full profile ›Company Intelligence Q&A
- What is OpenDNA's primary focus?
- OpenDNA focuses on developing an AI platform that combines clinical and genomic data analysis for polygenic diseases, aiming to predict and prevent heart disease.
- When was OpenDNA founded and by whom?
- OpenDNA was founded in September 2018 by Eran Feldhay and Erez Ornan.
- What was a key partnership announced by OpenDNA in 2023?
- In November 2023, OpenDNA partnered with PartnerMD to provide patients with AI-based genetic risk testing for cardiometabolic diseases.
- What was the outcome of OpenDNA's clinical study in 2023?
- In June 2023, OpenDNA announced the successful conclusion of a 150-patient clinical study.
- What research agreement did OpenDNA announce in 2022?
- In March 2022, OpenDNA announced a know-how and research agreement with Mayo Clinic as part of a pilot clinical study for cardiovascular disease prevention.